Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2138 in moderate to severe atopic dermatitis
NCT06585202Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATI-2138 in atopic dermatitis (AD), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Incidence and severity of treatment emergent adverse events at 14 weeks. Started Aug 2024; status: completed.
02
Drugs
ATI-2138
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06585202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585202.